Dr Lewis is Professor of Medicine and Director of Hepatology, Division of Gastroenterology , Medstar Georgetown University Hospital , Washington, DC. He has a long-standing interest in the field of drug-induced liver injury , pharmacovigilance and drug-safety . He currently serves as the Academic Lead for the IQ DILI Consortium , a partnership of academia, industry and FDA with a focus on hepatotoxicity.
Eric Cohen, MD is a Senior Medical Director in Pharmacovigilance at Abbvie Inc. and serves as the Chair of the Liver Internal Safety Advisory Group (ISAG). Dr. Cohen completed his fellowship training in Gastroenterology & Hepatology at Yale New Haven Medical Center (2009) and an advanced fellowship in Transplant Hepatology at Beth Israel Deaconess Medical Center (2010). He is an active member of IQ-DILI and is a key opinion leader in the field of hepatotoxicity.
As a hepatologist and Associate Director in CDER's Office of Pharmacovigilance and Epidemiology, Dr. Avigan has served as an expert consultant at FDA for the evaluation of drug-induced liver injury during the life cycle of drugs and biological agents. Earlier on, Dr. Avigan received his MD from McGill University. After his medical residency and GI fellowship, he trained as an NIH staff fellow and then was on the faculty of Georgetown University where he attended patients and was the principal investigator of NIH-funded grants to elucidate basic mechanisms in cell growth pathways.
I am a Professor of Medicine and Transplant Hepatologist at UCSF. My NIH-funded research focuses on the intersections of HIV, viral hepatitis, and hepatic steatosis.
Dr. Jorge Mera is the Director of Infectious Diseases for Cherokee Nation Health Services (CNHS), the largest tribally operated healthcare system in the United States. His efforts have been instrumental in the successful implementation of the Cherokee Nation Hepatitis C and HIV elimination programs. Dr. Mera is also an Associate Professor at the University of New Mexico Health Sciences Center and serves as the Medical Director for the South-Central AIDS Education and Training Center.
Richard So is dedicated to eliminating hepatitis B and liver cancer, with a vision of making the San Francisco Bay Area the first hepatitis B free region in the U.S. He has over a decade of experience in healthcare, including five years as Executive Director of Hep B Free, one of the country's leading hepatitis B organizations.
Dr. Debora Kogan-Liberman is an Associate Professor of Pediatrics in the Division of Pediatric Gastroenterology, Hepatology and Nutrition at the NYU Grossman School of Medicine . She is the Director of Pediatric Hepatology at the Hassenfeld Children's Hospital at NYU Langone Health. Her research interests include cholestatic liver disease in children, Fontan-associated liver disease and pediatric liver transplant.
Dr. Pandurangi is a pediatric transplant hepatologist and clinician-scientist dedicated to advancing translational research in biomarker discovery and precision medicine in pediatric liver disease. She is an assistant professor at UT Southewestern Medical Center/Children's Medical Center Dallas.
I am a board-certified Pediatric Gastroenterologist and Transplant Hepatologist and Section Chief of Hepatology and Transplant Medicine at Children's Mercy Hospital in Kansas City. I have a strong interest in translational research related to liver disease and transplantation, and novel therapeutics to treat disordered inflammation in the liver. My background in the lab includes basic research in dendritic cell biology, antigen presentation and cell-based immunotherapy.
Senior Transplant Hepatologist. Professor of Medicine and Surgery at Northwestern University. Special interest: Fontan Liver Disease and combined Heart Liver Transplants. Was a local PI of the Acute Liver Failure Study Group. <br>